Metopirone

Metyrapone, the active ingredient in Metopirone, is a 11β‑hydroxylase inhibitor presented as an oral tablet for oral administration. It blocks a key enzyme in cortisol synthesis, which is useful in diagnostic testing for adrenal insufficiency and, in some settings, for managing Cushing’s syndrome. The medication is prescribed by qualified healthcare professionals.

GNH USA supplies Metopirone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance.

Metyrapone is used in clinical practice and research to evaluate or modulate adrenal steroidogenesis. - Adrenal insufficiency (diagnostic testing): Helps assess cortisol production by temporarily inhibiting cortisol synthesis, allowing measurement of ACTH response. - Cushing’s syndrome (off‑label use): May be employed to reduce cortisol levels in patients where surgery or other therapies are unsuitable. - Endocrine research (pharmacologic challenge): Used as a tool to study adrenal axis dynamics in clinical investigations.

Metyrapone may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild stomach upset often reported. - Dizziness or light‑headedness: may occur especially when standing. - Headache: transient cranial discomfort. - Fatigue: general tiredness or weakness.

Serious or Rare Side Effects: - Hypertension: sudden increase in blood pressure requiring medical attention. - Adrenal crisis: severe cortisol deficiency leading to shock‑like symptoms. - Allergic reaction: rash, itching, swelling, or difficulty breathing.

When prescribing Metopirone, clinicians should consider several safety measures. - Dose adjustment: required in hepatic impairment. - Monitor: blood pressure and electrolyte levels during therapy. - Avoid: use in patients with uncontrolled hypertension. - Caution: may exacerbate hypokalemia; check potassium. - Pregnancy and lactation: safety not established; weigh risks. - Store at ambient temperature: keep in original container, protect from moisture and light.

Metyrapone can interact with other medicines; awareness of interaction severity is important.

Major Interactions (Avoid): - Ketoconazole: combined CYP inhibition may increase toxicity. - Rifampin: enzyme induction reduces metyrapone effectiveness. - Oral contraceptives: may alter steroid metabolism.

Moderate Interactions (Monitor Closely): - Antihypertensives: blood pressure changes may require dose adjustment. - Diuretics: risk of electrolyte imbalance, especially potassium. - Antidepressants (SSRIs): possible additive effects on cortisol axis.